Physician profile
Joseph Simpson
NPI 1558399378
$24,104.83
in general payments reported to CMS, 2019-2025
41 companies · $3,515 in 2025
The $3,515 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,207 · 2020: $2,591 · 2021: $2,799 · 2022: $3,037 · 2023: $3,900 · 2024: $4,057 · 2025: $3,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $21.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,450.69 |
| Education | $21.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,548.05 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $2,384.76 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,156.74 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,692.50 | 2019-2025 | Spravato |
| Abbvie INC. | $1,354.27 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $1,349.37 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $1,181.33 | 2019-2025 | Rexulti, Brintellix, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $1,131.73 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $1,042.39 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $955.67 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $791.27 | 2019-2023 | Lybalvi |
| Almatica Pharma LLC | $765.20 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $600.61 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $595.71 | 2021-2025 | Qelbree, Qelbree |
| Eisai INC. | $588.30 | 2020-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.